Fenofibrate
NDC Package 63304-444-90

11-digit billing NDC: 63304044490 · Billing unit: EA · 90 EA per package

Package Information

This product is EXCLUDED from the official NDC directory because the listing data was discontinued by the firm.

Fenofibrate is contraindicated in the following conditions:Severe renal impairment, including those with end-stage renal disease (ESRD) and those receiving dialysis [see Clinical Pharmacology (12.3)]. Marketed by Sun Pharmaceutical Industries, Inc., this product is identified by NDC 63304-444 and is authorized under FDA application ANDA201748.

Identification & Billing

NDC Package Code
63304-444-90
Package Description
90 CAPSULE in 1 BOTTLE
Product Code
11-Digit Billing Format
63304044490
Billing Unit
EA - Billing unit of "each" is used when the product is dispensed in discreet units.
Units Per Package
90 EA

Clinical Specifications

Proprietary Name
Fenofibrate
Dosage Form
-
Usage Information
Fenofibrateis contraindicated in the following conditions:Severe renal impairment, including those with end-stage renal disease (ESRD) and those receiving dialysis [see Clinical Pharmacology (12.3)]. Active liver disease, including those with unexplained persistent liver function abnormalities [see Warnings and Precautions (5.2)].Pre-existing gallbladder disease [see Warnings and Precautions (5.5)].Hypersensitivity to fenofibric acid, fenofibrate, or any of the excipients in fenofibrate capsules. Serious hypersensitivity reactions including anaphylaxis and angioedema have been reported with fenofibrate [see Warnings and Precautions (5.9)].

Regulatory & Marketing

Labeler Name
Sun Pharmaceutical Industries, Inc.
FDA Application #
ANDA201748
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
03-02-2015
End Marketing Date
10-31-2025
Listing Expiration
10-31-2025
Exclude Flag
D
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Other Available Packages

The following commercial packages are registered under the same Product NDC (63304-444). Click a package code to view its specific billing and regulatory data.

500 CAPSULE in 1 BOTTLE
30 CAPSULE in 1 BOTTLE

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 63304-444-90 identifies a specific commercial package of 90 capsule in 1 bottle of Fenofibrate, labeled by Sun Pharmaceutical Industries, Inc.. This is formulated for use and contains as the active substance.

Is this product currently listed with the FDA?

This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Sun Pharmaceutical Industries, Inc. on March 02, 2015. The current certification is valid through October 31, 2025.

How is this Sun Pharmaceutical Industries, Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 63304044490. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 90 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
63304-444-90
11-Digit CMS (5-4-2)
63304-0444-90

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.